Kangchen Pharmaceutical (01681) Annual Report View: A high-dividend pharmaceutical company with steady performance, rich products, and double revenue and profit

In 2023, Kangchen Pharmaceutical continued the steady growth trend of performance, achieving operating income of 2.59 billion yuan (unit, same below), up 10.7% year on year; gross profit of 1.92 billion yuan, up 9.0% year on year; gross margin of 74.2%; and net profit to mother of 785 million yuan, up 14.9% year on year.

Zhitong FinanceApr 1 19:51 ET

Keep integrity, innovate, and go farway丨Understand Kangchen Pharmaceutical (1681.HK)'s 2023 performance in one picture

Recently, Kangchen Pharmaceutical (1681.HK), the market leader in proprietary Chinese medicines for nephropathy, announced the results for the year ended December 31, 2023. The following will show you the 2023 annual results of Kangson Pharmaceuticals through a chart.

Gelonghui FinanceApr 1 09:39 ET

CONSUN PHARMA To Go Ex-Dividend On June 11th, 2024 With 0.3 HKD Dividend Per Share

March 30th - $CONSUN PHARMA(01681.HK)$ is trading ex-dividend on June 11th, 2024. Shareholders of record on June 12th, 2024 will receive 0.3 HKD dividend per share on June 21st, 2024. The ex-divid

moomoo NewsMar 30 05:05 ET

Consun Pharmaceutical Group Sees 15% Increase in 2023 Profit

Consun Pharmaceutical Group (HKG:1681) posted a 2023 profit attributable to shareholders of 784.5 million yuan, or 0.98 yuan per share, up from 682.9 million yuan, or 0.86 yuan per share, a year earli

MT NewswiresMar 29 05:14 ET

Conson Pharmaceutical (01681) proposes to adopt the 2024 share option plan

Zhitong Finance App News, Kangchen Pharmaceutical (01681) issued an announcement. The company adopted the 2013 share purchase plan on December 2, 2013. According to the terms of the 2013 Share Option Plan, unless otherwise terminated or amended, the 2013 Share Option Plan will be valid for 10 years from the date of its adoption and will expire on December 1, 2023. After the 2013 share option plan expires, no share options will be offered or granted. As of the date of this announcement, there were still 504.63,900 share options granted but not yet exercised in the 2013 share option plan. In view of the 2013 share option plan

Zhitong FinanceMar 28 05:29 ET

Kangchen Pharmaceutical (01681.HK): Net profit increased by 14.9% in 2023 to reach $780 million with final interest of HK$0.3 per share

On March 28, Ge Longhui | Kangchen Pharmaceutical (01681.HK) announced that in 2023, the Group achieved sales revenue of about RMB 2.59 billion, an increase of about 10.7% over the previous year; profit attributable to the company's equity shareholders was approximately RMB 780 million, an increase of about 14.9% over the previous year. Basic and diluted earnings per share were approximately RMB 0.99 and RMB 0.98 respectively. The Board proposed a final dividend of HK$0.3 per share for the year 2023. Looking at the business segment, Kangchen Pharmaceutical's sales revenue in 2023 was about RMB 2.2 billion, an increase of about 1 percent over the previous year

Gelonghui FinanceMar 28 00:07 ET